STAT reports that Biogen is preparing to announce results from a pivotal clinical trial of its experimental lupus therapy. The readout is expected soon, according to the source.
This matters for senior pharma and biotech executives because the trial outcome could influence development strategies, portfolio priorities and market competition in autoimmune disease. The results may also affect future investment and partnership opportunities in the lupus space.
